CAJ | 학술논문

JAK2 V617F基因突变阳性骨髓增殖性肿瘤(MPN)由真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)组成.文章聚焦于其危险度积分系统和治疗进展,包括一线及二线治疗、JAK2抑制剂、降细胞治疗、抗纤维化和其他单药或联合治疗.
JAK2 V617F기인돌변양성골수증식성종류(MPN)유진성홍세포증다증(PV)、원발성혈소판증다증(ET)화원발성골수섬유화(PMF)조성.문장취초우기위험도적분계통화치료진전,포괄일선급이선치료、JAK2억제제、강세포치료、항섬유화화기타단약혹연합치료.
JAK2 V617F gene mutation positive myeloproliferative neoplasms (MPN) consists of polycythemia vera (PV),essential thrombocythemia (ET) and primary myelofibrosis (PMF).This article focuses on their risk scoring systems and treatment including first-and second-line therapies,JAK2 inhibitors,cytoreduction,antifibrosis and other single-agent or combination therapy.